DiagnoCure study separates cancer risk groups

DiagnoCure (TSX:CUR) has released positive initial results of a multi-center clinical study of 241 stage 2 colon cancer patients. The first phase of the VITAR study demonstrated that the company’s Previstage GCC Colorectal Cancer Staging Test can stratify patients into high and low risk of recurrence groups, providing relevant and more accurate clinical information for [...]

DiagnoCure partner files prostate test with FDA

DiagnoCure’s (TSX:CUR) corporate partner has filed a premarket approvalapplication with the FDA for the Progensa PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer. DiagnoCure holds the worldwide rights to the PCA3 biomarker and in 2003, it granted an exclusive sub-license to [...]

DiagnoCure retains JMP Securities

DiagnoCure (TSX:CUR) has retained financial advisors JMP Securities to assist in determining the best option to drive the growth of its U.S.-based subsidiary, DiagnoCure Oncology Laboratories. “We are very excited to be partnering with JMP, and we are confident that their expertise will help us determine the most effective method to roll out our colorectal [...]

DiagnoCure Labs gets NY state permit

The New York State Department of Health has issued a clinical laboratory permit to DiagnoCure’s (TSX:CUR) Oncology Laboratories unit that allows the lab to test commercial samples originating in New York for the Previstage GCC colorectal staging test. “Previstage GCC is the only molecular test available to help better identify whether colorectal cancer has spread [...]